Clinical trials: ALK-rearrangement
Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
This phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after…
- Conditions
- Large B-Cell Lymphoma With IRF4 Rearrangement, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent ALK-Positive Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type
- Trial name
- NCT06834373
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- 7 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Carcinoma, Non-Small-Cell Lung
Detection of Either the EML4-ALK Gene Rearrangements or the T790M EGFR Mutation in the Plasma of Advanced NSCLC Patients
Demonstrate feasibility of detection of EML4-ALK fusion transcripts and T790M EGFR mutation from exosomes in the circulation of Non-Small Cell Lung Cancer (NSCLS) patients.
- Trial name
- NCT03236675
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Exosome Diagnostics, Inc.
ALK Gene Rearrangement, ALK Gene Translocation
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma…
- Conditions
- ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Trial name
- NCT02201992
- Testing
- Clinical Observation, Crizotinib, Laboratory Biomarker Analysis
- Where
- 1,618 sites in United States, Guam and 1 more
- Volunteers
- 166 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Non-Small Cell Lung Cancer (NSCLC)
Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
The purpose of the study was to learn whether the study treatment (capmatinib), which already shows efficacy and safety in non-Chinese patients, could help Chinese patients with controlling their lung cancer in a safe way.
- Trial name
- GeoMETry-C (NCT04677595)
- Testing
- Capmatinib
- Where
- 17 sites in China
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Anaplastic Large-Cell Lymphoma
A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib
The purpose of this study is to determine the efficacy and safety of crizotinib combined with CHOP chemotherapy for patients with ALK(+) Systemic Anaplastic Large Cell Lymphoma.
- Trial name
- NCT02487316
- Testing
- crizotinib
- Where
- China
- Sponsor
- Jun Zhu
Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive
Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC
BioEXALK is a prospective study evaluating the biological characteristics of advanced ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the national EXPLORE ALK cohort (GFPC 03-2019), a…
- Trial name
- BIOEXALK (NCT05122806)
- Testing
- RNAseq
- Where
- 46 sites in France
- Volunteers
- 100 people
- Sponsor
- Groupe Francais De Pneumo-Cancerologie